FindTrial
Sign In

Reduction of surgical-site infection in hip and knee replacement: the influence of perioperative nasal ointment with antibiotics and soap with alcohol solotion in decreasing the amount of infections.

Reduction of surgical-site infection in hip and knee arthroplasty: the influence of perioperative mupirocin nasal ointment and chlorhexidine soap in a double-blind, randomized, multicentre, placebo-controlled study. - µp-trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-022701-17-NL
Enrollment
Unknown
Registered
2015-11-10
Start date
2015-11-17
Completion date
Unknown
Last updated
2015-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of hip and knee, prevention of surgical site infections after arthroplasty

Interventions

Trade Name: Mupirocine neuszalf 2% 20mg/ml Product Name: mupirocin Pharmaceutical Form: Nasal ointment CAS Number: 12650-69-0 Other descriptive name: MUPIROCIN Concentration unit: mg milligram(s) Conc

Sponsors

Isala
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All competent patients undergoing primary hip or knee replacement surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 3000 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 9000

Exclusion criteria

Exclusion criteria: non competent patiens allergy to one of the products

Design outcomes

Primary

MeasureTime frame
Main Objective: patient who need an primairy hip or knee arthroplasty;Secondary Objective: none;Primary end point(s): decrease in the number of infections with staphylococcal aureus as agent;Timepoint(s) of evaluation of this end point: two years after surgery—

Secondary

MeasureTime frame
Secondary end point(s): decrease in the number of infections with other microbial agents responsible;Timepoint(s) of evaluation of this end point: two years after surgery—

Countries

Netherlands

Contacts

Public Contactorthopedic ward

Isala clinics

r.rolink@isala.nl

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026